Log in

Relevant bibliographies by topics / Request for a grant of a patent / Journal articles

To see the other types of publications on this topic, follow the link: Request for a grant of a patent.

Journal articles on the topic 'Request for a grant of a patent'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Request for a grant of a patent.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tullis, Terry K. "Current intellectual property issues in nanotechnology." Nanotechnology Reviews 1, no. 2 (2012): 189–205. http://dx.doi.org/10.1515/ntrev-2012-0501.

Full text

Abstract:

AbstractTo the extent that the USPTO issues a proliferation of broad and potentially overlapping nanotechnology patents, the development of a nanotechnology patent thicket could impede the licensing process required for further innovation. If the contractor refuses the federal agency’s request, the agency can grant a license to the applicant itself if “the contractor or assignee has not taken, or is not expected to take within a reasonable time, effective steps to achieve practical application of the subject invention in such field of use” or if “action is necessary to meet requirements for pu

APA, Harvard, Vancouver, ISO, and other styles

2

Schuhmann, Carmen, Marianne C. Snijdewind, Lisa van Duijvenbooden, and Geert E. Smid. "“If Only I Could Start All over…” A Case Study of Spiritual Care Provision to a Patient with a Psychiatric Disorder Requesting Physician-Assisted Dying in The Netherlands." Religions 12, no. 9 (2021): 672. http://dx.doi.org/10.3390/rel12090672.

Full text

Abstract:

In a growing number of countries, legislation permits physicians—under strict conditions—to grant a request for physician-assisted dying (PAD). Legally allowing for the possibility of granting such a request is in accordance with central humanistic values such as respect for autonomy and self-determination. The Netherlands is one of few countries where severe suffering from a psychiatric illness qualifies as a ground for a request for PAD. Central in this article is a case description of spiritual care provision in the Netherlands by a humanist healthcare chaplain to a patient requesting PAD b

APA, Harvard, Vancouver, ISO, and other styles

3

Lantushenko, Viktoriya, and Edward F. Nelling. "How do institutional investors respond to patent announcements?" Managerial Finance 44, no. 12 (2018): 1446–65. http://dx.doi.org/10.1108/mf-12-2017-0536.

Full text

Abstract:

Purpose The purpose of this paper is to examine institutional investor demand for shares of firms that announce patents. Design/methodology/approach There are three important dates in the process of obtaining a patent. First, a patent filer requests the right for intellectual property on the application date. Next, the content of a patent becomes publicly available on the publication date, if authorized by the US Patent and Trademark Office. Third, once the patent is validated, it is issued on the grant date. The authors focus on the publication date, as it marks the time when the patent-speci

APA, Harvard, Vancouver, ISO, and other styles

4

Khalil, Sarwat, Madiha Fida, Douglas W. Challener, et al. "1834. Incremental Diagnostic Value of 16S Ribosomal RNA Gene Polymerase Chain Reaction/Sanger Sequencing in Clinical Practice." Open Forum Infectious Diseases 6, Supplement_2 (2019): S44. http://dx.doi.org/10.1093/ofid/ofz359.096.

Full text

Abstract:

Abstract Background Polymerase chain reaction (PCR)/sequencing targeting the 16S ribosomal RNA (rRNA) gene to detect bacteria in normally sterile tissues and fluids has become increasingly popular in clinical medicine. This culture-independent technique can detect bacteria that are nonviable or difficult to cultivate using conventional methods. The clinical value of this type of testing is not well defined. We aimed to assess the diagnostic value of 16S rRNA PCR/Sanger sequencing as a clinical diagnostic assay at Mayo Clinic. Methods This is an interim analysis of the first 173 of 478 patients

APA, Harvard, Vancouver, ISO, and other styles

5

Moch, Kenneth I. "Ethical Crossroads: Expanded Access, Patient Advocacy, and the #SaveJosh Social Media Campaign." Medicine Access @ Point of Care 1 (January 2017): maapoc.0000019. http://dx.doi.org/10.5301/maapoc.0000019.

Full text

Abstract:

Expanded access programs raise complex ethical dilemmas regarding the use of experimental medicines to treat life-threatening medical conditions – issues for which there are no simple, monolithic solutions. Beyond the risks to an individual, how does society or a company balance the immediate needs of a critically ill individual versus the potential needs of many future patients? This article offers insights into and learning experiences from the case of a 7-year-old boy whose family sought access to an experimental antiviral medicine being developed by Chimerix, where the author was Chief Exe

APA, Harvard, Vancouver, ISO, and other styles

6

Kaszubska, Katarzyna. "Compulsory Licensing under India’s New Model Bilateral Investment Treaty." Review of Market Integration 9, no. 3 (2017): 139–54. http://dx.doi.org/10.1177/0974929217744466.

Full text

Abstract:

The traditional lack of patent protection for pharmaceutical products allowed India’s generic sector to expand and become ‘the pharmacy of the world’ supplying affordable medicines to both developed and developing countries. With the entry into force of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement in 2005, the mechanism of compulsory licensing was incorporated as a flexibility to ensure that the protection of intellectual property (IP) rights does not undermine the public access to affordable medicine. Following the issuance of the first compulsory licence by the

APA, Harvard, Vancouver, ISO, and other styles

7

Bevis, Kerri S., Elizabeth Ann Kvale, Gabrielle Rocque, et al. "Understanding causes of distress in women with gynecologic cancer." Journal of Clinical Oncology 33, no. 29_suppl (2015): 94. http://dx.doi.org/10.1200/jco.2015.33.29_suppl.94.

Full text

Abstract:

94 Background: Lay patient navigators can screen patients using a distress tool (DT) to identify and address multiple patient concerns. Patient-reported distress can be used to characterize the needs of patients with ovarian, endometrial, and cervical cancer through all phases of care from initial diagnosis through active treatment and into survivorship. Methods: The Patient Care Connect Program (PCCP) includes 12 cancer centers throughout Alabama, Mississippi, Georgia, Florida, and Tennessee and navigates Medicare beneficiaries with cancer. Within the PCCP, navigators documented distress leve

APA, Harvard, Vancouver, ISO, and other styles

8

Lin, Michael Y., Tiffany Wiksten, Alexander Tomich, Mary K. Hayden, and John Segreti. "974. Impact of Mandatory Infectious Disease (ID) Specialist Approval on Hospital-Onset Clostridium difficile (HO-CDI) Testing and Infection Rates: Results of a Pilot Study." Open Forum Infectious Diseases 5, suppl_1 (2018): S38—S39. http://dx.doi.org/10.1093/ofid/ofy209.090.

Full text

Abstract:

Abstract Background The 2017 IDSA C. difficile guidelines recommend the use of nucleic acid amplification testing alone for detection of HO-CDI if appropriate stool specimens are collected (e.g., patients not receiving laxatives and ≥3 unformed stools in 24 hours). The potential role of ID specialists in enforcing appropriate C. difficile testing is unclear. Methods At a single academic hospital, we performed a pilot study of an ID specialist-led approval process for C. difficile testing. During the baseline period (January 2016 and November 2017), HO-CDI testing appropriateness was enforced u

APA, Harvard, Vancouver, ISO, and other styles

9

Bourrier, Nicole, Ivan Landego, Mandy Squires, et al. "A Descriptive Analysis of Obinutuzumab Usage in a Single Canadian Centre." Blood 132, Supplement 1 (2018): 5838. http://dx.doi.org/10.1182/blood-2018-99-113422.

Full text

Abstract:

Abstract Background:Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in North America with the majority of patients being over the age of 70 (Goede et al, 2014). CLL is a heterogeneous disease with some patients undergoing treatment at time of diagnosis, while others follow along a more indolent, asymptomatic course. When indicated, the choice of treatment is based on the patient's functional status, renal function and other comorbidities (Shanafelt, 2013). Previous studies have shown that unfit patients treated with Obinutuzumab plus Chlorambucil have shown prolongation of pr

APA, Harvard, Vancouver, ISO, and other styles

10

McClellan, M. B. "Request for Grant Applications." JAMA: The Journal of the American Medical Association 288, no. 17 (2002): 2112—b—2112. http://dx.doi.org/10.1001/jama.288.17.2112-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

McClellan, Mark B. "Request for Grant Applications." JAMA 288, no. 17 (2002): 2112. http://dx.doi.org/10.1001/jama.288.17.2112-jfd20011-3-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Martani, Andrea. "Right to Try and Physician Assisted Suicide: Similar or Different?" Studia Universitatis Babeş-Bolyai Bioethica 66, Special Issue (2021): 122. http://dx.doi.org/10.24193/subbbioethica.2021.spiss.80.

Full text

Abstract:

"In the last few years, the debate whether terminally ill patients should have access to experimental treatments without governmental supervision has intensified. The so-called “Right-to-Try” (RTT) doctrine has become popular especially in the United States, where the federal parliament passed a bill allowing such practices. As many other policies concerning patients’ autonomy in end-of-life circumstances, the appropriateness of RTT has often been challenged. In this context, some authors recently put forward the argument that states where it is allowed to request physician assisted suicide (P

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "AABIP Research Grant—Request for Applications." Journal of Bronchology & Interventional Pulmonology 19, no. 2 (2012): 85. http://dx.doi.org/10.1097/lbr.0b013e318253927d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Benesova, K., L. Diekmann, H. M. Lorenz, K. Jordan, and J. Leipe. "OP0270 TRHEUMA REGISTRY EXPLORES CHARACTERISTICS AND SUITABLE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS (IRAES)." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 168.1–169. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3790.

Full text

Abstract:

Background:Reports of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICPi) have recently attracted new attention to the complex interrelations of malignancies andrheumatic and musculoskeletal diseases (RMDs). Since those two entities represent two sides of a dysregulated immune response, further research on rheumatic irAEs and mechanisms underlying the better tumor response rates in irAE-affected patients may contribute to a better understanding of the different pathophysiology characterizing tumor and rheumatic disease.Objectives:Given the

APA, Harvard, Vancouver, ISO, and other styles

15

Palangkaraya, Alfons, Paul H. Jensen, and Elizabeth Webster. "Applicant behaviour in patent examination request lags." Economics Letters 101, no. 3 (2008): 243–45. http://dx.doi.org/10.1016/j.econlet.2008.08.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

De Cock, D., P. Durez, D. Elewaut, B. Lauwerys, R. Westhovens, and P. Verschueren. "THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 322. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6192.

Full text

Abstract:

Background:The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining data collection from all Belgian patients with Rheumatoid Arthritis (RA) on advanced therapy, together with a drug reimbursement request. Therapy choice after initial 2 classical synthetic DMARD failure is left to the treating rheumatologist in Belgium.Objectives:To investigate first-line therapy choices for tumor necrosis factor inhibitor (TNFi) biologic (b) DMARDs, non-TNFi bDMARDs or targeted synthetic (ts) DMARDs via patient characteristics and initial treatment respon

APA, Harvard, Vancouver, ISO, and other styles

17

Reynolds, C., D. Barrera, D. Q. Vu, et al. "An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7610. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7610.

Full text

Abstract:

7610 Background: The development of nab-paclitaxel has circumvented many of the infusion difficulties that are associated with standard solvent based paclitaxel (in cremophor). In this open label, phase II trial, patients with advanced (stage IIIB or IV) nonsquamous NSCLC received the combination of nab-paclitaxel, carboplatin and bevacizumab. Methods: 50 patients were enrolled between October 2005 and April 2006. Patients received intravenous (IV) nab-paclitaxel 300 mg/m2, carboplatin IV AUC=6, and bevacizumab 15 mg/kg on day 1 of each 21-day cycle. Responding patients received at least 4 cyc

APA, Harvard, Vancouver, ISO, and other styles

18

Chhabra, Param Pal singh, Manpreet Hora, and Karthik Ramachandran. "Patent Grant Delays and Future Innovative Activities." Academy of Management Proceedings 2019, no. 1 (2019): 16192. http://dx.doi.org/10.5465/ambpp.2019.16192abstract.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Aoki, Reiko, and Yossi Spiegel. "Pre-grant patent publication and cumulative innovation." International Journal of Industrial Organization 27, no. 3 (2009): 333–45. http://dx.doi.org/10.1016/j.ijindorg.2008.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bian, Renjun. "Post-grant patent review in China: an empirical analysis." Queen Mary Journal of Intellectual Property 10, no. 3 (2020): 339–75. http://dx.doi.org/10.4337/qmjip.2020.03.04.

Full text

Abstract:

With a series of policies to stimulate innovation and patent activities, China has become a world leader in both patent applications and patent litigation. These major developments, together with the escalated US-China trade tensions, have made China an integral but controversial venue for international patent protection. The Chinese patent system, especially its detailed practice and cases, is in need of a comprehensive empirical study. This article analyzed 8766 Chinese patent invalidity cases decided between 2014 and 2016, which, together with my prior work on patent infringement lawsuits,

APA, Harvard, Vancouver, ISO, and other styles

21

Drivas, Kyriakos, Irene Fafaliou, Elpiniki Fampiou, and Demetrius Yannelis. "The effect of patent grant on the geographic reach of patent trade." Journal of High Technology Management Research 26, no. 1 (2015): 58–65. http://dx.doi.org/10.1016/j.hitech.2015.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Dutt, Raman, Prakhar Rathi, and Vinita Krishna. "Novel mixed-encoding for forecasting patent grant duration." World Patent Information 64 (March 2021): 102007. http://dx.doi.org/10.1016/j.wpi.2020.102007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Schjødt Jørgensen, T., R. L. Hansen, B. Pouls, B. Van den Bemt, C. Sjowall, and L. E. Kristensen. "AB0321 EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1459.1–1459. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2814.

Full text

Abstract:

Background:Anti-tumour necrosis factor (anti-TNF) adherence is suboptimal and impacted by multiple psychological, practical and physical barriers, such as patient needle phobia, lack of confidence in self-administration skills and forgetting injection dates (1,2). ava®, a reusable electro-mechanical self-injection device (e-Device) developed for certolizumab pegol (CZP) administration, aims to overcome some of these barriers.Objectives:The objective of this study was to explore the clinical retention rate of an e-Device aimed at empowering chronic arthritis patients using CZP.Methods:Patients

APA, Harvard, Vancouver, ISO, and other styles

24

Anderson, Christopher, and Declan Butler. "US rejects French request to reopen AIDS patent deal." Nature 359, no. 6393 (1992): 262. http://dx.doi.org/10.1038/359262c0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sengupta, Mayuree. "How tall is your claim? Strategically acing patent scope." Strategic Direction 36, no. 4 (2020): 1–3. http://dx.doi.org/10.1108/sd-10-2019-0204.

Full text

Abstract:

Purpose The article examines strategically directing the breadth of scope of a patent and hazards of litigation vis-à-vis the length of claims for innovating firms. Design/methodology/approach This paper enumerates latest literature on assessing patent scope and hence protection afforded to firm innovations. Based on prior research findings, this paper proposes to maintain a balanced and nuanced approach to claim drafting to assure grant of patent while minimizing litigation threats. Findings To strategically manage patent grant and minimize litigation threat, firms would better take a leaf ou

APA, Harvard, Vancouver, ISO, and other styles

26

Cao, Siwei, Zhen Lei, and Junbyoung Oh. "How do firms utilize the deferred patent examination system? Evidence from Korea." European Journal of Innovation Management 22, no. 2 (2019): 234–56. http://dx.doi.org/10.1108/ejim-03-2018-0066.

Full text

Abstract:

Purpose The purpose of this paper is to investigate firm behaviors on patent examination request under the deferred patent examination system in Korea. The authors examine firm decisions on whether and when to request patent examinations when they face both uncertainty about invention’s value and market competition. Design/methodology/approach The authors provide a simple theoretical model and test a couple of hypothesis using Korea patent data. The authors employ KIPO (Korean intellectual patent office) patent applications data during 2006–2009 and incorporate it with firm financial data retr

APA, Harvard, Vancouver, ISO, and other styles

27

Rose, K. "P84 Pediatric oncology studies triggered by the united states (US) food and drug administration (FDA) and the european union (EU) european medicines agency (EMA) aim at labels, not at improved treatment. Some harm young patients by exposing them to substandard monotherapy instead of combination treatment." Archives of Disease in Childhood 104, no. 6 (2019): e52.1-e52. http://dx.doi.org/10.1136/archdischild-2019-esdppp.122.

Full text

Abstract:

BackgroundBoth FDA and EMA reward/demand pediatric oncology studies. Do they advance pediatric cancer care?MethodsWe analysed publications of FDA representatives,1–3 FDA-triggered pediatric oncology studies in the literature and in www.clinicaltrials.gov,4 and FDA/EMA pediatric reports.5–6ResultsFDA authors express two key assumptions: (1) children, defined as < 17y, need separate proof of efficacy;1–3 (2) with the exception of chronic myelogenous leukema, the biology of cancer in children is different from adult cancer.1 FDA-triggered studies investigated single cytoxics agents in heavily

APA, Harvard, Vancouver, ISO, and other styles

28

Neu, Timm. "Post-Grant Patent Examination after the America Invents Act." IIC - International Review of Intellectual Property and Competition Law 44, no. 4 (2013): 445–55. http://dx.doi.org/10.1007/s40319-013-0051-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Frolova, Anna. "PREPARATION OF A SUBSIDY REQUEST FOR A CULTURAL PROJECT: NOVICE GRANT-SEEKERS' TYPICAL MISTAKES." Proceedings of Altai State Academy of Culture and Arts 4 (2020): 73–77. http://dx.doi.org/10.32340/2414-9101-2020-4-73-77.

Full text

Abstract:

The paper briefly reviews various mistakes that are typical for unexperienced government grant-seekers in subsidy requests for execution of socially significant non-profit projects and programs in cultural sector addressed to expert committees of grant competitions. The key points of argument-based denials of subsidies for execution of such projects outlined in critical comments, expert reports and reviews gave for declined requests as well as the author's own remarks are described

APA, Harvard, Vancouver, ISO, and other styles

30

Graham, Stuart J. H., and Dietmar Harhoff. "Separating patent wheat from chaff: Would the US benefit from adopting patent post-grant review?" Research Policy 43, no. 9 (2014): 1649–59. http://dx.doi.org/10.1016/j.respol.2014.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Manu, Thaddeus. "Deploying pre-grant patent opposition mechanisms in Africa to monitor abuse of the patent system." Commonwealth Law Bulletin 41, no. 3 (2015): 399–421. http://dx.doi.org/10.1080/03050718.2015.1073605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Rein, Frederick H., and Joseph B. Crystal. "The America Invents Act: Post-grant review and paragraph IV certifications." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 9, no. 1 (2012): 5–8. http://dx.doi.org/10.1177/1741134311435766.

Full text

Abstract:

This article discusses the new post-grant review of a patent, a process which will become available on September 16, 2012 pursuant to the America Invents Act – but for non-business method patents, applies only to patents having an effective filing date on or after March 16, 2013. In particular, this article sets forth various factors to be considered by a generic pharmaceutical company in deciding whether to petition for post-grant review of a patent or proceed with a standard Hatch-Waxman litigation.

APA, Harvard, Vancouver, ISO, and other styles

33

Garsson, Ross Spencer, and Chinh H. Pham. "Strategies for post-grant reviews and other proceedings for challenging an issued patent." Nanotechnology Reviews 1, no. 6 (2012): 541–44. http://dx.doi.org/10.1515/ntrev-2012-0072.

Full text

Abstract:

AbstractIn the past, there have been other means for challenging a patent (or prospective patent) at the United States Patent and Trademark Office (USPTO). These included preissuance submissions of prior art and ex parte reexaminations, which continue to be available. With the enactment of the Leahy-Smith America Invents Act (AIA) on September 16, 2011, additional means have been provided to entities so that they now have a greater set of potential procedures to challenge and neutralize patents – procedures that are both more economical and will take less time to resolve. Under the AIA, there

APA, Harvard, Vancouver, ISO, and other styles

34

McMahon, Aisling. "Patents, Governance and Control: Ethics and the Patentability of Novel Beings and Advanced Biotechnologies in Europe." Cambridge Quarterly of Healthcare Ethics 30, no. 3 (2021): 529–42. http://dx.doi.org/10.1017/s0963180120001073.

Full text

Abstract:

AbstractThis article focuses primarily on to what extent novel beings, and particularly, beings which display something akin to human consciousness or agency would be (or should be) patentable under current European patent law. Patents grant the patent holder a right to exclude others from using the patented invention for the period of patent grant (usually 20 years). This allows the patent holder to control how that invention can or cannot be used by others downstream, granting patent holders a governance like function over the patented technology for the duration of the patent. Accordingly,

APA, Harvard, Vancouver, ISO, and other styles

35

Kim, Seung-Jo. "A Request for a Patent Correction During a Patent Invalidation Trial Pursuant to the Revoking Judgement." Journal of Intellectual Property 7, no. 2 (2012): 1–28. http://dx.doi.org/10.34122/jip.2012.06.7.2.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Dutt, Raman, and Vinita Krishna. "Forecasting the Grant Duration of a Patent using Predictive Analytics." International Journal of Computer Applications 178, no. 51 (2019): 1–7. http://dx.doi.org/10.5120/ijca2019919398.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Drivas, Kyriakos, and Ioannis Kaplanis. "The role of international collaborations in securing the patent grant." Journal of Informetrics 14, no. 4 (2020): 101093. http://dx.doi.org/10.1016/j.joi.2020.101093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gaessler, Fabian, Dietmar Harhoff, and Stefan Sorg. "Patents and Cumulative Innovation – Evidence from Post-Grant Patent Oppositions." Academy of Management Proceedings 2017, no. 1 (2017): 12800. http://dx.doi.org/10.5465/ambpp.2017.302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Yates, M., A. Clark, R. Watts, A. Macgregor, and S. Mackie. "FRI0198 OCULAR MORBIDITY IN PATIENTS WITH PMR AND GCA IN THE UK - A CPRD STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 682.2–683. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4402.

Full text

Abstract:

Background:Visual loss is the most serious consequences of a diagnosis of polymyalgia rheumatic (PMR) and giant cell arteritis (GCA). To date, information on the occurrence of eye disease in GCA has been based almost exclusively on small hospital-based patient series. Furthermore the lack of control group for these studies results in a lack of relative risk estimates for visual loss.There are no accurate data on the prevalence and nature of eye complications among patients in the community. Patients with GCA may be exclusively managed in the primary care setting without referral for either tem

APA, Harvard, Vancouver, ISO, and other styles

40

Manu, Thaddeus. "Building national initiatives of compulsory licences." Journal of International Trade Law and Policy 14, no. 1 (2015): 23–48. http://dx.doi.org/10.1108/jitlp-07-2014-0015.

Full text

Abstract:

Purpose – The purpose of this paper is to examine the extent to which developing countries could build national initiatives of compulsory licences. Design/methodology/approach – The focus of this article is only on developing countries. The author reflects on the Indian patent jurisprudence regarding the operational relationship between the general principles applicable to working of patented inventions locally and the grant of compulsory licences. The discussion that follows is based on a review of the case: Bayer Corporation versus Natco Pharma with a view to presenting a model for developin

APA, Harvard, Vancouver, ISO, and other styles

41

Cho, Hye-Kyung, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, et al. "1255. In Vitro Activity of Vancapticin against Methicillin-Resistant Staphylococcus aureus from Periprosthetic Joint Infection." Open Forum Infectious Diseases 7, Supplement_1 (2020): S645. http://dx.doi.org/10.1093/ofid/ofaa439.1439.

Full text

Abstract:

Abstract Background The vancapticins are modified vancomycin derivatives developed by adding membrane targeting motifs to the C-terminus of vancomycin. We determined the in vitro activity of a lead vancapticin candidate against periprosthetic joint infection-associated methicillin-resistant Staphylococcus aureus (MRSA) in the planktonic and biofilm states, and the effect of adding 0.002% polysorbate 80 (P-80; Sigma-Aldrich) on vancapticin susceptibility testing. Methods Thirty-seven clinical isolates of MRSA collected at Mayo Clinic (Rochester, Minnesota) were studied. Vancapticin minimum inhi

APA, Harvard, Vancouver, ISO, and other styles

42

Rocque, Gabrielle Betty, Richard A. Taylor, Elizabeth Ann Kvale, et al. "Guiding lay navigation using the distress thermometer." Journal of Clinical Oncology 32, no. 31_suppl (2014): 195. http://dx.doi.org/10.1200/jco.2014.32.31_suppl.195.

Full text

Abstract:

195 Background: The Commission on Cancer will require distress evaluation in 2015, given growing emphasis on psychosocial care. We report on a novel use of the distress thermometers (DTs) to frame navigator-patient interactions. Methods: Thirty-eight lay (non-clinical) navigators were trained to utilize a comprehensive distress thermometer to evaluate patients in the Patient Care Connect program (PCCP). The PCCP is a 12-center network throughout AL, MS, GA, FL and TN that serves Medicare patients ≥ 65 with cancer. During patient interactions, navigators assess causes of distress and requests f

APA, Harvard, Vancouver, ISO, and other styles

43

L. Mayburd, Anatoly, Govind Kedia, Haydn W. Evans, and Pritesh C. Kaslival. "Patent Landscape of Countermeasures Against Smallpox and Estimation of Grant Attraction Capability Through Patent Landscape Data." Recent Patents on Anti-Infective Drug Discovery 5, no. 3 (2010): 240–54. http://dx.doi.org/10.2174/157489110793348758.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Flynn, Sean, Aidan Hollis, and Mike Palmedo. "An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries." Journal of Law, Medicine & Ethics 37, no. 2 (2009): 184–208. http://dx.doi.org/10.1111/j.1748-720x.2009.00365.x.

Full text

Abstract:

Not all intellectual property rights grant the right to exclude that is indicative of “property rules,” as that term was used by Guido Calabresi and A. Douglas Melamed in their seminal article. Some intellectual property rights are “liability rules,” in which the right holder has an entitlement to compensation for use of the protected invention, not a right to preclude the use. Although patent laws normally grant a right to exclude others from use of the protected invention as a default, most countries’ laws allow the government to convert the patent property rule into a liability rule through

APA, Harvard, Vancouver, ISO, and other styles

45

Memon, Kamran, Khalid Mohammadani, Noor Ain, et al. "Demand Forecasting DBA Algorithm for Reducing Packet Delay with Efficient Bandwidth Allocation in XG-PON." Electronics 8, no. 2 (2019): 147. http://dx.doi.org/10.3390/electronics8020147.

Full text

Abstract:

In a typical 10G-Passive Optical Network (XG-PON), the propagation delay between the Optical Network Unit (ONU) and Optical Line Terminal (OLT) is about 0.3 ms. With a frame size of 125 μs, this amounts to three frames of data in the upstream and three frames of data in the downstream. Assuming no processing delays, the grants for any bandwidth requests reach the ONU after six frames in this request-grant cycle. Often, during this six-frame delay, the queue situation is changed drastically, as much, more data would arrive in the queue. As a result, the queued data that is delayed loses its sig

APA, Harvard, Vancouver, ISO, and other styles

46

Adhani, Oktaviana, and Bagiyo Atmaja. "KEABSAHAN PEMBATALAN HIBAH AKIBAT PEMBERI HIBAH JATUH MISKIN." Jurnal Komunikasi Hukum (JKH) 6, no. 1 (2020): 95. http://dx.doi.org/10.23887/jkh.v6i1.23443.

Full text

Abstract:

A grant is a gift that starts in effect since it is implemented. not infrequently the grant as a voluntary gift raises problems that occur because there are other parties who raise objections to the grant. This study analyzes the validity of grants to minors represented by their mothers and the legal position of cancellation of grants due to poor grants. The research method used is normative juridical by using the statutory approach and conceptual approach. The results of the study showed that the grants for the inheritance of the giver of grants to minors and received by their mothers were le

APA, Harvard, Vancouver, ISO, and other styles

47

Jelisavac, Sanja. "International regulation of intellectual property rights." Medjunarodni problemi 56, no. 2-3 (2004): 279–303. http://dx.doi.org/10.2298/medjp0403279j.

Full text

Abstract:

Intellectual property refers to creations of the mind: inventions, literary and works of art, as well as symbols, names, images, and designs that are used in commerce. Intellectual property is divided into two categories industrial property, which includes inventions (patents), trademarks industrial designs, and geographic indications of source; and copyright which includes literary and works of art such as novels, poems and plays films, musical works, works of art such as drawings, paintings, photographs and sculptures, and architectural designs. Rights related to copyright include those of p

APA, Harvard, Vancouver, ISO, and other styles

48

Di Bella, Nicholas, Raymond Taetle, Kathryn S. Kolibaba, et al. "Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma." Blood 112, no. 11 (2008): 1572. http://dx.doi.org/10.1182/blood.v112.11.1572.1572.

Full text

Abstract:

Abstract This study was designed to evaluate the efficacy and safety of bortezomib as monotherapy in patients (pts) with indolent B-cell lymphoma who have relapsed following, or who are refractory to, rituximab therapy. A total of 60 patients enrolled and 59 were treated with 1.3 mg/m2 of bortezomib (IV bolus over 3–5 secs) Days 1, 4, 8, and 11 for up to eight 21-day cycles; pts with a CR could receive 4 additional cycles. Pts with &lt;CR entered the maintenance phase with bortezomib administered on Days 1, 4, 8, and 11 of each 42- day cycle until progression; 55 patients completed 2 or mo

APA, Harvard, Vancouver, ISO, and other styles

49

Harhoff, Dietmar. "Patent Quality and Examination in Europe." American Economic Review 106, no. 5 (2016): 193–97. http://dx.doi.org/10.1257/aer.p20161093.

Full text

Abstract:

This paper reports on effects of recent administrative reforms at the European Patent Office (EPO). In EPO-granted patents, claims numbers started to decline in 2008 when new claims fees became effective, claims sections in patents became shorter, and independent claims longer and presumably more specific. The grant rate remained at relatively low levels, but the EPO was unable to stem the use of divisional filings. The developments at the EPO point to a high private value of delay options. Delay may be achieved either by making use of explicit statutory rules or by other means, such as filing

APA, Harvard, Vancouver, ISO, and other styles

50

Okada, Yoshimi, and Sadao Nagaoka. "Global Spread of Pharmaceutical Patent Protection: Micro Evidence from the International Equivalents of Drug Patents in Japan." Millennial Asia 8, no. 1 (2017): 26–47. http://dx.doi.org/10.1177/0976399616686864.

Full text

Abstract:

We investigate the global spread of pharmaceutical patent protection as acquired by firms, based on a novel global patent database for all significant medical drugs, including biologics, introduced in Japan. It gives us the propensity of filing and grant rate for each country for patents granted in Japan. The major findings of the study are as following. Both the filing propensity to and the grant rate of major Asian countries approached those of the OECD economies by the early 2000s for chemical substance inventions. However, substantial heterogeneity with respect to other drug inventions sti

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!